Privately-held biotech Allegro Ophthalmics said today that its Del Mar Phase IIb stage 2 trial met its primary endpoint. The study assessed Luminate as a sequential therapy or combo therapy in 80 patients with diabetic macular edema.
The San Juan Capistrano, Calif.-based company’s Luminate integrin peptide therapy treats neovascular retinal diseases by targeting integrin receptors, which are involved in cell signaling, regulation and in building new blood vessels.
Get the full story at our sister site, Drug Delivery Business News.
The post Allegro’s diabetic macular edema trial meets primary endpoint appeared first on MassDevice.